Market Cap 567.28B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.45
Forward PE 20.82
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 3,889,195
Avg Vol 7,720,828
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 59%
Beta 0.26
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
kiwitc2000
kiwitc2000 Jun. 17 at 7:06 PM
$JNJ Entering the support zone around 232. Curious to see if that holds before entering.
0 · Reply
Orchard
Orchard Jun. 17 at 5:48 PM
$MRNA The company makes poison Vaxx that has destroyed people’s lives. Every day more and more formally suppressed data shows this “gene therapy” goes into ovaries. $JNJ couldn’t even make baby powder w/out asbestos and sunscreen without cancer chemicals $PFE with cholesterol scam drugs $LLY trying to own GLPs. Ozempic and Monjero are made from Gila Monster venom compounds. They tried to hide all the deaths and side effects and you morons keep trusting them.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 17 at 5:02 PM
2 · Reply
Skimman
Skimman Jun. 17 at 2:19 PM
$JNJ little OVERBLOWN here
0 · Reply
Suite510
Suite510 Jun. 17 at 2:10 PM
$JNJ $KVUE $SPX June 16, 2026 😬💰 J&J Fails To Undo $65.5M Verdict In Minn. Talc Cancer Case A Minnesota state judge on Monday upheld a $65.5 million verdict awarded to a mother of three children who had claimed that Johnson & Johnson's talc products exposed her to asbestos and contributed to her cancer, saying that the jury's decision was supported by the evidence at trial.
1 · Reply
TraderDaKing
TraderDaKing Jun. 17 at 1:56 PM
$ELTP $PFE $JNJ $SPCX $GME Elite Pharmaceuticals’ Sequestox: Poised to Become the Gold Standard in Drug Space Pending FDA Approval. Elite Pharmaceuticals is generating significant buzz in the pharmaceutical industry with its promising new drug, Sequestox. This innovative treatment is currently pending FDA approval and is widely anticipated to set a new benchmark in its therapeutic category. Go ELTP !.... More News Coming.....
0 · Reply
Skimman
Skimman Jun. 17 at 1:49 PM
$JNJ WTF....
1 · Reply
BarkingPuppy
BarkingPuppy Jun. 17 at 1:43 PM
$PFE $JNJ New Buy-out and or merger.
0 · Reply
RetailWolfie
RetailWolfie Jun. 17 at 1:28 PM
$JNJ showed a beautiful wick touching the 50DMA as a retest Still holding this support area, looking to see another breakout attempt!
0 · Reply
cwEWF
cwEWF Jun. 17 at 9:34 AM
$JNJ favors rally in 5 of (1), while dips remain above 6.01.2026 low to extend rally It favors rally towards 259.3 or higher from daily #Bluebox area to extend bull run started from January-2025 low. Are you long from #bluebox area or still waiting? #Elliottwave #JNJ
0 · Reply
Latest News on JNJ
Johnson & Johnson presents first results from ENERGY study

2026-06-11T09:26:54.000Z - 6 days ago

Johnson & Johnson presents first results from ENERGY study


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 9 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to acquire Firefly Bio for $1B in cash

2026-06-08T12:14:56.000Z - 9 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 9 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 27 days ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 6 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 6 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 7 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 7 weeks ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: AGM 2026


kiwitc2000
kiwitc2000 Jun. 17 at 7:06 PM
$JNJ Entering the support zone around 232. Curious to see if that holds before entering.
0 · Reply
Orchard
Orchard Jun. 17 at 5:48 PM
$MRNA The company makes poison Vaxx that has destroyed people’s lives. Every day more and more formally suppressed data shows this “gene therapy” goes into ovaries. $JNJ couldn’t even make baby powder w/out asbestos and sunscreen without cancer chemicals $PFE with cholesterol scam drugs $LLY trying to own GLPs. Ozempic and Monjero are made from Gila Monster venom compounds. They tried to hide all the deaths and side effects and you morons keep trusting them.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 17 at 5:02 PM
2 · Reply
Skimman
Skimman Jun. 17 at 2:19 PM
$JNJ little OVERBLOWN here
0 · Reply
Suite510
Suite510 Jun. 17 at 2:10 PM
$JNJ $KVUE $SPX June 16, 2026 😬💰 J&J Fails To Undo $65.5M Verdict In Minn. Talc Cancer Case A Minnesota state judge on Monday upheld a $65.5 million verdict awarded to a mother of three children who had claimed that Johnson & Johnson's talc products exposed her to asbestos and contributed to her cancer, saying that the jury's decision was supported by the evidence at trial.
1 · Reply
TraderDaKing
TraderDaKing Jun. 17 at 1:56 PM
$ELTP $PFE $JNJ $SPCX $GME Elite Pharmaceuticals’ Sequestox: Poised to Become the Gold Standard in Drug Space Pending FDA Approval. Elite Pharmaceuticals is generating significant buzz in the pharmaceutical industry with its promising new drug, Sequestox. This innovative treatment is currently pending FDA approval and is widely anticipated to set a new benchmark in its therapeutic category. Go ELTP !.... More News Coming.....
0 · Reply
Skimman
Skimman Jun. 17 at 1:49 PM
$JNJ WTF....
1 · Reply
BarkingPuppy
BarkingPuppy Jun. 17 at 1:43 PM
$PFE $JNJ New Buy-out and or merger.
0 · Reply
RetailWolfie
RetailWolfie Jun. 17 at 1:28 PM
$JNJ showed a beautiful wick touching the 50DMA as a retest Still holding this support area, looking to see another breakout attempt!
0 · Reply
cwEWF
cwEWF Jun. 17 at 9:34 AM
$JNJ favors rally in 5 of (1), while dips remain above 6.01.2026 low to extend rally It favors rally towards 259.3 or higher from daily #Bluebox area to extend bull run started from January-2025 low. Are you long from #bluebox area or still waiting? #Elliottwave #JNJ
0 · Reply
Wallstfan
Wallstfan Jun. 16 at 7:12 PM
$KO added under $ 80. I think people will start to take profits in tech and flock to names like $JNJ $ABBV $KO
0 · Reply
OptionSamurai
OptionSamurai Jun. 16 at 2:51 PM
$JNJ appears in our scan that looks for calls that will explode if the stock goes to analyst target. Analysts rating is BUY and the target price is 12.7% away📈. Call 240.0, 21-Aug-26 has: Max loss of 3.1% compared to holding shares and Breakeven is 6.4% away. If the stock hits the target, the call will profit 200% 🔥🔥🔥. 👉 Create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jun. 16 at 10:54 AM
$JNJ favors pullback in 4 red against 6.01.2026 low before continue rally to extend (1) The bulls are looking for target above 259.3 or higher in daily to extend January-2025 sequence, while dips remain above 220.38 low from daily #Bluebox area. #Elliottwave #JNJ
0 · Reply
red_bull7
red_bull7 Jun. 16 at 12:38 AM
$JNJ I'd love to see this retest the trendline and then start the next wave higher.
0 · Reply
notreload_ai
notreload_ai Jun. 15 at 5:00 PM
CMS has proposed making its Medicare Drug Price Negotiation Program permanent from 2029, tightening rules on combo drugs. $JNJ, $BMY, and $MRK shares fell on the news, but analysts see limited long-term impact due to legal challenges and diversification. https://notreload.xyz/xy/cms-to-make-medicare-drug-price-negotiations-permanent-in-2029/
0 · Reply
MorganHoratio
MorganHoratio Jun. 15 at 4:41 PM
Here are some of the most prominent themes that our team is focusing on: Healthcare: $OSCR $HNGE $UNH $JNJ $HTFL This Healthcare watchlist captures the vital rotating theme of mid-2026: smart money is spilling out of legacy defensive value into high-pricing-power digital health and clinical AI disruptors. The underlying fundamentals here are stellar. Digital MSK leader $HNGE just hiked its full-year 2026 growth outlook to a rampant 40% at its June 10 Investor Day. Meanwhile, AI coronary pioneer $HTFL raised its fiscal guidance following a blowout 41% YoY Q1 revenue jump on rapid product adoption. Concurrently, insurtech leader $OSCR is holding multi-year highs, while legacy staples like $UNH (navigating its recent FTC insulin settlement) and $JNJ reset to deep structural support. Are you sheltering in cash-cow defensive giants like $UNH, or accumulating high-growth AI health turnarounds like $HNGE and $HTFL on this necessary dip?
0 · Reply
clan
clan Jun. 15 at 4:24 PM
$MNKD For the good of all Mannkind. Ignore the whiny lying trolls🧌. 2026 is Mannkind's "year of inflection". Think hockey stick 🏒 ...and multiple shots on goal🥅. $SPY $QQQ $JNJ
0 · Reply
RunnerSignals
RunnerSignals Jun. 15 at 3:20 AM
Goldman screen $IOT $BTSG $ULTA $JNJ everyone sees the ai trade. the more interesting signal is where analysts are finding durable growth, margin expansion worth watching where institutional flows are concentrating. https://stocksrunner.com/news/2026-06-14-goldman-sachs-highlights-stocks-positioned-to-lead-the-market
0 · Reply
AdamBrennan2
AdamBrennan2 Jun. 15 at 2:01 AM
$LLY pricing in 16.6% free cash flow growth, i think the growth will be much more than this with reta $NVO $JNJ $ABBV $NVS
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 13 at 2:51 PM
0 · Reply
focafoca99
focafoca99 Jun. 13 at 10:45 AM
$JNJ announced strong Phase 3 MonumenTAL-3 data, with TALVEY + DARZALEX FASPRO achieving up to 81% PFS and 89% OS at 24 months. https://www.rapidticker.com/news/jnj-new-talvey-talquetamab-tgvs-plus-1ffcd0
0 · Reply
topstockalerts
topstockalerts Jun. 12 at 8:47 PM
Leerink reported a rebound in U.S. prescription trends for the week ended June 5, 2025, with the overall pharmaceutical market growing 10% week-over-week after an 8% decline during the Memorial Day period. Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) posted prescription growth of 46% year-over-year over one week, 51% over four weeks, and 57% over 12 weeks. Novo Nordisk's semaglutide products (Ozempic/Wegovy) recorded growth of 22%, 21%, and 18%, respectively. Wegovy prescriptions rose 10% week-over-week, while Zepbound increased 9%. Foundayo generated roughly 20,000 prescriptions in its ninth week on the market, up 17% sequentially but still well below oral Wegovy's approximately 81,000 prescriptions during its ninth week. Oral Wegovy reached around 159,000 prescriptions in its 22nd launch week, although Leerink noted IQVIA data likely understates demand by excluding certain direct-to-consumer channels. $LLY $NVO $ABBV $JNJ
0 · Reply